Our company

BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins for chronic diseases and immune-therapies. It is a cutting-edge and mature solution for oral formulations, not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies, vaccines, immunotherapies etc.


Essence of BioLingus the Company and its Technology - An interview of BioLingus CEO Yves Decadt by European CEO at London Stock Exchange.
Yves Decadt explains the innovative technology that takes injectable medicines and transforms them into pills.


MAY 2016

BioLingus has been selected as the winner of the 2016 award in the section "MOST INNOVATIVE BIOTECH COMPANY" from the European CEO magazine.
[Read More]



The Cytokine Stabilisation and Slow Release (CSSR) technology is the "mother" of the BioLingus technologies.


Through advanced "bio-engineering", the BioLingus SEED Technology is mimicking what is happening in nature in a plant SEED.


The OPUS (Oral Peptide Utility System) is our technology application to orally (sublingually) or via the mucosum administer peptides which have no immunomodulatory mode of action.


Due to the fact that BioLingus drug administration is sublingual, and the use of a specific carrier molecule in the BioLingus formulation, the BioLingus technology is particularly effective for sublingual immuno therapy.

Corporate Partnerships

Corporate Partnerships

To further exploit the potential of the BioLingus Technology, we are interested in exploring partnerships with other pharmaceutical companies. Aside from pharmaceutical companies, we are also interested in working with animal health companies" (with adjusted formulations) and food companies working on innovative food supplements.

Together we unlock the potential of the BioLingus Technology, and thus transform current standard practices in the administration of peptides and proteins.


Main Office
BioLingus AG

Grossmatt 6
CH-6052 Hergiswil NW